During Friday's Mad Money program, Jim Cramer gave a nod to NovoCure Ltd ( NVCR) , the oncology company that is pioneering new therapies. Let's check out the charts and indicators. 
In this daily bar chart of NVCR, below, we can see that shares of NVCR have tumbled lower the past three months. Prices had a wild ride to a late June peak and then suddenly gapped lower to start the decline from around $220 to just $110 now - a 50% wipeout in just a few months. The slopes of the 50-day moving average and the slower-to-react 200-day line are negative or bearish. The 50-day line has also crossed below the 200-day line at the beginning of September for a late dead or death sell signal. Moving averages always lag the price action.
The On-Balance-Volume (OBV) line has declined along with the weak price action and suggests that sellers of NVCR have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator has been below the zero line since early July but is lining up for a cover shorts buy signal and a bullish divergence when compared to the price action.
In this weekly Japanese candlestick chart of NVCR, below, we can see that the recent candles are showing lower shadows. These shadows are not long and dramatic but they do show a shift in "attitude" versus earlier candles. Prices are retesting support from late 2020 which may or may not hold. We'll see.
The MACD oscillator is below the zero line but has begun to narrow.
In this daily Point and Figure chart of NVCR, below, we can see that the software is projecting a possible or tenative price target in the $105 area. A rebound to $116 may delay or nix further declines.
Bottom line strategy: NVCR has suffered a significant decline that hurts traders with a high cost basis but may also attract longer-term investors with a different time horizon. Let's wait and see if NVCR can hammer out a bottom pattern around the $110 area.
